EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effect of hydration schedules on dose‐limiting toxicity in patients with head and neck squamous cell carcinoma treated with cisplatin

Anouk W M A Schaeffers iD, Cassimy B van Neerven, Dorieke van Balen, Mirjam Crul iD, Marije Slingerland, Saskia A C Luelmo, Jan Paul de Boer, Jens Voortman, Arjan D van Zuilen, Remco de Bree, Lot A Devriese

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Anouk W M A Schaeffers und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgical Oncology, Division Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Net…. Hauptthemen laut MEDLINE: Cisplatin, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The aim of this study was to determine if head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin chemoradiotherapy and short hydration (SH) experience less dose‐limiting toxicity (DLT) and receive more cisplatin than those with medium hydration (MH) or long hydration (LH).

Methods

Baseline characteristics, cumulative cisplatin dose and toxicities were collected. Differences between LH, MH and SH were tested, with separate analyses for triweekly 100 mg/m 2 cisplatin and weekly 40 mg/m 2 cisplatin. Mixed models assessed the hydration schedule's effect on cumulative dose.

Results

A total of 389 patients were included. DLT occurrence was comparable between hydration groups ( P = .060), but DLT type differed ( P = .007). Nephrotoxicity was common with LH and MH (n = 11, 61% and n = 26, 45%, respectively), and ototoxicity with SH (n = 35, 36%). DLT occurrence in triweekly patients differed between LH and MH (n = 18, 64% vs n = 25, 32%, P = .004), but not between MH and SH ( P = .171) or LH and SH ( P = .055) patients. Cisplatin dose differed between LH and MH (median 200 vs 300, P = .008) as well as between LH and SH (median 200 vs 300, P = .024) but not between MH and SH ( P = .429) patients. Hydration had no effect on dose ( F = 2.09, P = .125).

Conclusions

DLT cause differed between hydration groups, with less nephrotoxicity but more ototoxicity in HNSCC patients with SH. Triweekly cisplatin LH patients had more DLT and lower cumulative dose compared to MH and SH, but no hydration effect in general on dose was found.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsAntineoplastic AgentsFluid TherapyHumansMaleFemaleMiddle AgedAgedChemoradiotherapyAdultDose-Response Relationship, DrugRetrospective StudiesOtotoxicityDrug Administration Schedule

Stichwörter der Autor:innen

chemoradiotherapycisplatindose‐limiting toxicityhead and neck oncologyhydrationnephrotoxicity

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Head and Neck Surgical Oncology, Division Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Department of Pharmacology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Department of Medical Oncology, Leiden University Medical Center Leiden, Leiden, The Netherlands.
  • Department of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Department of Medical Oncology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands.

ORCID-Profile: Anouk W M A Schaeffers, Mirjam Crul

Zitieren

APA

Schaeffers, A. W. M. A., van Neerven, C. B., van Balen, D., Crul, M., Slingerland, M., Luelmo, S. A. C., de Boer, J. P., Voortman, J., van Zuilen, A. D., de Bree, R., & Devriese, L. A. (2025). Effect of hydration schedules on dose‐limiting toxicity in patients with head and neck squamous cell carcinoma treated with cisplatin. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70015

Vancouver

Schaeffers AWMA, van Neerven CB, van Balen D, Crul M, Slingerland M, Luelmo SAC, et al. Effect of hydration schedules on dose‐limiting toxicity in patients with head and neck squamous cell carcinoma treated with cisplatin. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70015

BibTeX
@article{Schaeffers2025,
  author = {Schaeffers, Anouk W M A and van Neerven, Cassimy B and van Balen, Dorieke and Crul, Mirjam and Slingerland, Marije and Luelmo, Saskia A C and de Boer, Jan Paul and Voortman, Jens and van Zuilen, Arjan D and de Bree, Remco and Devriese, Lot A},
  title = {Effect of hydration schedules on dose‐limiting toxicity in patients with head and neck squamous cell carcinoma treated with cisplatin},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70015}
}
Kostenlos starten →